On February 4, 2022 Prescient Therapeutics Limited (ASX: PTX) engaged in evolving personalized therapies for cancer reported for the December quarter of the current fiscal year (Press release, Prescient Therapeutics, FEB 4, 2022, View Source;utm_medium=rss&utm_campaign=prescient-therapeutics-asxptx-tables-impressive-results-for-december-quarter [SID1234607768]). The results reflect Prescient has anchored itself at a strong clinical and financial position in the industry. It worked its way through the quarter achieving crucial clinical and business development milestones.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The action-packed December quarter
During the quarter, Prescient made persistent progress in several anti-cancer therapy programs and projects aiming overall advancement in cancer treatment for patients worldwide.
The ASX-listed firm ended the quarter with a cash balance of AU$14.77 million. During the quarter, the firm received a tax refund of AU$1.33 million under Australian Government Research and Development.
Prescient presented new OmniCAR pre-clinical data at California’s Cell & Gene Meeting on the Mesa, one of the prominent platforms for international medical and investment community engaged in development of novel cell therapies. The new data included the prime features of OmniCAR to generate CAR-T cell therapies that can be controlled post-infusion; re-armed; and redirected from one cancer antigen to another. Also, significant dose-response cancer killing activity and high potency were demonstrated.
Physician-scientist Dr Marco Davila of the Moffitt Cancer Center and bioengineering expert Professor Andrew Tsourkas of the University of Pennsylvania joined firm’s multi-disciplinary expert international Scientific Advisory Board (SAB) in November 2021.
After the reporting period, Prescient has been successful in securing accreditation from the Office of the Gene Regulator (OTGR) for OmniCAR clinical studies. As per the Gene Technology Act 2000, the Instrument of Accreditation is a requisite for a firm in Australia to hold clinical trials that involve gene-edited cells, like CAR-T therapies.
The clinical-stage oncology company is looking forward to go beyond the ambit of growth and development and achieve bigger milestones in the coming quarters of the year. It will continue to work on its key clinical and pre-clinical trials to bring in relief for cancer patients.
The firm is dedicatedly working to evolve next-generation of targeted therapies that can help doctors in cancer treatment. New developments will also give way to long-term shareholder value.